Update TDP-43 protein page with comprehensive content

Migration, Crosslink

📖

Update TDP-43 protein page with comprehensive content

active

wiki page Created: 2026-04-02T07:19:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-tdp-43

📖 Wiki Page

protein2951 wordssynced 2026-04-02

Update TDP-43 protein page with comprehensive content

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TDP-43 (TAR DNA-Binding Protein 43)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[TARDBP](/genes/tardbp)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q13148" target="_blank">Q13148</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/2N2C" target="_blank">2N2C</a>, <a href="https://www.rcsb.org/structure/4BS2" target="_blank">4BS2</a>, <a href="https://www.rcsb.org/structure/5MDI" target="_blank">5MDI</a>, <a href="https://www.rcsb.org/structure/7D41" target="_blank">7D41</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>43 kDa (414 amino acids)</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Nucleus (physiological), cytoplasm (disease)</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Heterogeneous nuclear ribonucleoprotein (hnRNP) family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Amyotrophic Lateral Sclerosis](/diseases/als), [Frontotemporal Dementia](/diseases/ftd), [LATE](/diseases/late), [Corticobasal Degeneration](/diseases/cbd)</td>
</tr>
</table>

TDP-43 (TAR DNA-Binding Protein 43)

Overview

...

Update TDP-43 protein page with comprehensive content

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TDP-43 (TAR DNA-Binding Protein 43)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[TARDBP](/genes/tardbp)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q13148" target="_blank">Q13148</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/2N2C" target="_blank">2N2C</a>, <a href="https://www.rcsb.org/structure/4BS2" target="_blank">4BS2</a>, <a href="https://www.rcsb.org/structure/5MDI" target="_blank">5MDI</a>, <a href="https://www.rcsb.org/structure/7D41" target="_blank">7D41</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>43 kDa (414 amino acids)</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Nucleus (physiological), cytoplasm (disease)</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Heterogeneous nuclear ribonucleoprotein (hnRNP) family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Amyotrophic Lateral Sclerosis](/diseases/als), [Frontotemporal Dementia](/diseases/ftd), [LATE](/diseases/late), [Corticobasal Degeneration](/diseases/cbd)</td>
</tr>
</table>

TDP-43 (TAR DNA-Binding Protein 43)

Overview

TDP-43 (TAR DNA-binding protein of 43 kDa) is a highly conserved RNA/DNA-binding protein encoded by the [TARDBP](/genes/tardbp) gene on chromosome 1p36.2[@ou1995]. It is a founding member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family and plays essential roles in RNA metabolism, including transcription, splicing, RNA stability, and transport[@buratti2010]. The protein's name derives from its initial identification as a binding protein for the TAR (Trans-Activation Response) element of HIV-1.

TDP-43 has emerged as a central player in neurodegeneration research due to its central role in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)[@neumann2006]. Pathological TDP-43 inclusions are the defining neuropathological feature in ~95% of ALS cases and ~50% of FTD cases, representing the most common proteinopathy in these disorders. Additionally, TDP-43 pathology is observed in over 20 other neurodegenerative conditions, including Alzheimer's disease (in a subset of cases), Parkinson's disease, and limbic-predominant age-related TDP-43 encephalopathy (LATE)[@johnson2024].

Protein Structure and Domain Organization

TDP-43 is a 414-amino acid protein with distinct structural domains that mediate its diverse functions[@lukavsky2013]:

N-Terminal Domain (Residues 1-102)

The N-terminal domain (NTD) serves multiple essential functions:

Protein dimerization: The NTD mediates homodimer formation, essential for functional activity[@chang2019]
Nuclear localization: Contains a basic nuclear localization signal (NLS, residues 82-98)
DNA binding: Mediates binding to TAR DNA sequences
Interactions: Provides docking sites for various protein partners

RNA Recognition Motifs (RRM1 and RRM2)

Two highly conserved RRMs (residues 106-176 and 191-259) form the RNA-binding core:

RRM1 (RNA Recognition Motif 1):
Binds UG-rich RNA sequences with high affinity
Recognizes single-stranded DNA with similar specificity
Essential for most RNA-processing functions
Key residues: Phe147, Phe149, Tyr155 (aromatic stack)
RRM2 (RNA Recognition Motif 2):
Contributes to RNA binding specificity
Works cooperatively with RRM1
Contains the sequence-motif recognition surface

Glycine-Rich C-Terminal Domain (Residues 274-414)

The C-terminal region contains prion-like properties:

Low-complexity domain: Highly enriched in glycine, glutamine, asparagine, and serine
Prion-like behavior: Capable of forming amyloid-like aggregates
Protein interaction hub: Mediates interactions with numerous hnRNP proteins
Nuclear export signal (NES): Multiple leucine-rich export sequences

Three-Dimensional Structure

Crystal structures and NMR studies have revealed key structural features[^7]:

| Domain | Structure | Key Features |
|--------|-----------|--------------|
| NTD | Dimeric | Forms antiparallel dimer |
| RRM1 | βαββαβ fold | Classic RRM fold, RNA-binding surface |
| RRM2 | βαββαβ fold | Similar to RRM1, less characterized |
| CTD | Intrinsically disordered | Prion-like, aggregation-prone |

Key PDB structures include [2N2C](https://www.rcsb.org/structure/2N2C) (RRM1+RRM2), [4BS2](https://www.rcsb.org/structure/4BS2) (full-length RRM domain), and [5MDI](https://www.rcsb.org/structure/5MDI) (disease mutant).

Normal Physiological Functions

TDP-43 is a multifunctional RNA-binding protein essential for neuronal health[^8]:

Transcriptional Regulation

HIV-1 TAR binding: The protein was originally identified binding to HIV-1 TAR DNA element
Gene transcription: Modulates transcription of numerous cellular genes
Chromatin association: Can associate with chromatin via DNA binding
[NF-κB](/entities/nf-kb) regulation: Controls inflammatory gene expression

Alternative Splicing

TDP-43 is a master regulator of alternative splicing[@buratti2001]:

CFTR exon 9 skipping: Classic model of TDP-43-mediated regulation
SMN2 exon 7 inclusion: Critical for spinal muscular atrophy
APOER2 exon 19: Regulates neuronal signaling
thousands of targets: Genome-wide studies reveal >30% of transcripts are TDP-43 targets

Specific splicing events regulated by TDP-43:

Neuronal genes: Include many synaptic proteins
Apoptotic regulators: Bcl-x, Mcl-1 isoforms
Cytoskeletal proteins: [Tau](/proteins/tau) (MAPT) alternative splicing

RNA Stability and Transport

mRNA stabilization: Binds to 3' UTRs to protect mRNAs from degradation
miRNA processing: Interacts with Drosha/Dicer complexes
mRNA trafficking: Facilitates transport to dendritic/axonal compartments
Translation regulation: Can repress or activate translation

Stress Response

Under cellular stress, TDP-43 plays protective roles[@liuyesucevitz2010]:

Stress granule formation: Rapidly localizes to stress granules (SGs)
mRNA protection: Sequesters specific mRNAs during stress
Translation arrest: Contributes to translational shutdown
Cell survival: SG formation may be protective initially

Post-Translational Modifications

TDP-43 undergoes numerous PTMs that regulate its function and aggregation[^11]:

Phosphorylation

Pathological marker: Phosphorylation at Ser409/Ser410 is a hallmark of disease
Other sites: Ser379, Ser383, Ser389, Thr153, Ser379
Kinases: Casein kinases (CK1, CK2), [CDK5](/proteins/cdk5), GSK3β implicated
Functional impact: Affects aggregation, localization, clearance

Ubiquitination

Ubiquitin positive: Pathological inclusions are ubiquitinated
K48 linkages: Predominantly K48-linked chains in inclusions
K63 linkages: May have regulatory functions
Proteasomal degradation: Tagged for degradation

Acetylation

Lysine acetylation: Multiple lysines can be acetylated
p300/CBP: Major acetyltransferase
Functional impact: Reduces RNA binding, may promote aggregation

Truncation

C-terminal fragments: 25-35 kDa fragments accumulate in disease
Proteolytic cleavage: By caspases, calpains, and other proteases
Aggregation-prone: Fragments seed full-length aggregation

Other Modifications

SUMOylation: Modifies solubility and aggregation
Methylation: Arginine methylation affects RNA binding
Oxidation: Oxidative stress promotes aggregation

Mechanisms of Pathogenesis

TDP-43 proteinopathy involves multiple interconnected pathogenic mechanisms[^12]:

1. Loss of Nuclear Function

Splicing disruption: Misregulation of critical splicing events
mRNA instability: Loss of mRNA stabilization
Nuclear depletion: Sequestration away from nuclear functions
Cryptic exon inclusion: Aberrant splicing of non-coding exons

2. Cytoplasmic Aggregation

Inclusion formation: Cytoplasmic TDP-43 inclusions
Aggregation mechanism: Nucleated polymerization
Seeding: Aggregates can template further aggregation
Strain variation: Different conformations in different diseases

3. Stress Granule Dysregulation

Mermaid diagram (expand to render)

4. Mitochondrial Dysfunction

Mitochondrial transport: Impaired axonal mitochondria trafficking
Energy deficit: Reduced ATP production
[Apoptosis](/mechanisms/apoptosis): Increased susceptibility to apoptotic stimuli
Calcium dysregulation: Altered mitochondrial calcium handling

5. Axonal Transport Defects

Transport machinery: Disruption of dynein/dynactin function
Synaptic deficits: Impaired synaptic vesicle trafficking
RNP granules: Abnormal transport of RNA granules
Neurotrophin deprivation: Reduced BDNF signaling

6. Neuroinflammation

Astrocyte activation: Reactive astrogliosis
Microglial activation: Inflammatory cytokine release
Peripheral immune: Systemic inflammatory markers
Non-cell autonomous: Glia contribute to degeneration

TDP-43 in Specific Diseases

Amyotrophic Lateral Sclerosis (ALS)

ALS is a rapidly progressive neurodegenerative disease affecting upper and lower motor [neurons](/entities/neurons)[@taylor2016]:

Prevalence: ~5 per 100,000 worldwide
Age of onset: Typically 55-65 years
Survival: 2-5 years from symptom onset
Genetics: ~10% familial, ~90% sporadic

TDP-43 pathology in ALS:

Cytoplasmic inclusions in motor neurons
Also in glial cells ([astrocytes](/cell-types/astrocytes), microglia)
Associated with:
Motor neuron loss in ventral horn
Degeneration of corticospinal tracts
Skeletal muscle denervation

Genetic forms:

TARDBP mutations: ~4% of familial ALS
[C9orf72](/genes/c9orf72) expansions: Most common genetic cause
FUS, SOD1, ATXN2: Other genetic causes
TDP-43 pathology in most genetic forms

Clinical features:

Progressive muscle weakness
Muscle atrophy
Fasciculations
Spasticity
Dysphagia
Respiratory failure

Frontotemporal Dementia (FTD)

FTD encompasses a group of disorders characterized by frontotemporal lobe degeneration[@rascovsky2011]:

Prevalence: ~10-15 per 100,000 (under 65)
Subtypes:
Behavioral variant FTD (bvFTD)
Primary progressive aphasia (PPA)
Semantic variant PPA
Nonfluent/agrammatic PPA

TDP-43 pathology in FTD:

Type A: Moderate numbers of lentiform NIIs
Type B: Many small NIIs
Type C: Neuronal intranuclear inclusions
Type D: Numerous lentiform NIIs

Clinical-pathological correlations:

Type A: Typically bvFTD
Type B: Often ALS-FTD
Type C: Often semantic variant PPA

LATE is a recently recognized TDP-43 proteinopathy affecting older adults[@nelson2019]:

Prevalence: ~25% of individuals over 85
Clinical presentation: Amnestic dementia syndrome
Pathology:
TDP-43 in amygdala, [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex)
Often comorbid with AD pathology
Staging:
Stage 1: Amygdala only
Stage 2: Hippocampus
Stage 3: Neocortex

Other Associated Conditions

| Disease | TDP-43 Pathology | Notes |
|---------|-----------------|-------|
| Alzheimer's Disease | ~30-50% of cases | Particularly in older patients |
| Parkinson's Disease | Subset | Often limbic |
| Huntington's Disease | Some cases | Rare |
| CTE | Most cases | With [tau](/proteins/tau) pathology |
| AGD | Co-pathology | Argyrophilic grains |

Therapeutic Strategies

Multiple therapeutic approaches target TDP-43 pathology[^16]:

1. Reducing TDP-43 Expression

Antisense oligonucleotides: ASOs targeting TARDBP mRNA
RNAi approaches: siRNA/shRNA delivery
Gene therapy: AAV-delivered knockdown

2. Modulating Aggregation

Small molecule inhibitors: Target aggregation pathway
Peptide-based inhibitors: β-sheet breaker peptides
Chaperone enhancement: Hsp90, Hsp70 modulators

3. Restoring Splicing Function

Splicing modifiers: Correct aberrant splicing
Antisense therapeutics: Redirect splicing patterns
mRNA stabilizers: Compensate for loss of function

4. Enhancing Clearance

[Autophagy](/entities/autophagy) inducers: Rapamycin, trehalose
[UPS](/mechanisms/ubiquitin-proteasome-system) modulators: Enhance proteasomal function
Immunotherapy: Antibody-based approaches

5. Neuroprotective Strategies

Anti-glutamatergic: Riluzole, amantadine
Anti-oxidants: CoQ10, edaravone
Anti-inflammatory: Microglial modulators

6. Symptomatic Treatments

Muscle spasticity: Baclofen, tizanidine
Pseudobulbar affect: Dextromethorphan/quinidine
Respiratory support: Non-invasive ventilation

TDP-43 Strain Diversity

Emerging evidence indicates TDP-43 forms distinct pathological strains[^17]:

Strain Types

ALS-type strains: Characteristic of classical ALS
FTD-type strains: Associated with frontotemporal dementia
LATE-type strains: Specific to limbic-predominant pathology

Implications

Diagnosis: Strain typing may enable precise diagnosis
Biomarkers: Strain-specific biomarkers in development
Therapy: Strain-specific therapeutic approaches

Biomarkers

TDP-43 serves as a biomarker in multiple formats[^18]:

Fluid Biomarkers

CSF TDP-43: Total and phosphorylated forms
[Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Marker of neurodegeneration
CSF/serum ratios: Diagnostic potential

Imaging

Structural MRI: Characteristic patterns of atrophy
PET: In development for TDP-43 imaging
Diffusion tensor imaging: White matter changes

Genetic Testing

TARDBP sequencing: For familial cases
C9orf72 testing: Most common genetic cause
Genetic counseling: Important for families

Key Mutations

Over 50 pathogenic TARDBP mutations have been identified[^19]:

| Mutation | Location | Effect | Phenotype |
|----------|----------|--------|------------|
| A315T | NTD | Reduced splicing | ALS |
| G348C | RRM1 | RNA binding | ALS/FTD |
| Q331K | RRM1 | Mitochondrial | ALS |
| M337V | RRM1 | Cytoplasmic | ALS |
| K383I | RRM2 | Aggregation | FTD |
| N390D | RRM1 | Splicing | ALS/FTD |

Animal Models

Various animal models have been developed[^20]:

Transgenic mice: Wild-type and mutant TDP-43
Drosophila: Genetic models
Zebrafish: Developmental models
iPSC models: Patient-derived neurons

Recent Research Developments

2025-2026 Advances

Phase separation: New understanding of LLPS in disease
Strain biology: Characterization of distinct strains
Therapeutic delivery: Improved ASO delivery to CNS
Biomarkers: Validation of fluid biomarkers
iPSC models: Patient-derived disease models

Key Publications

[Neumann et al., Ubiquitinated TDP-43 in ALS and FTD (2006)](https://pubmed.ncbi.nlm.nih.gov/17023659/). Science. 2006;314(5796):130-133.

[Lagier-Tourenne & Cleveland, Rethinking ALS (2009)](https://doi.org/10.1016/j.tins.2009.07.004). Trends Neurosci. 2009;32(10):529-533.

[Renton et al., C9orf72 and ALS (2011)](https://pubmed.ncbi.nlm.nih.gov/21944778/). Neuron. 2011;72(2):245-256.

[Lee et al., TDP-43 pathology (2012)](https://doi.org/10.1007/s00401-012-0970-0). Acta Neuropathol. 2012;124(6):739-751.

[Johnson et al., TDP-43 and FTD (2009)](https://pubmed.ncbi.nlm.nih.gov/19609692/). J Neuropathol Exp Neurol. 2009;68(8):857-864.

[Buratti & Baralle, TDP-43 functions (2010)](https://doi.org/10.1016/j.molmed.2010.02.004). Mol Med. 2010;16(3-4):125-134.

[Polymenidou et al., TDP-43 targets (2011)](https://pubmed.ncbi.nlm.nih.gov/22002745/). Nat Neurosci. 2011;14(4):459-468.

[Alberti et al., Phase separation in neurodegeneration (2019)](https://doi.org/10.1038/s41580-019-0147-x). Nat Rev Neurosci. 2019;20(11):651-660.

[Nelson et al., LATE-NC (2019)](https://doi.org/10.13039/100007057). Brain. 2019;142(5):1503-1527.

[McAlary et al., TDP-43 aggregation (2019)](https://doi.org/10.1007/s00401-019-02000-4). Acta Neuropathol. 2019;137(4):511-524.

External Links

UniProt: [Q13148](https://www.uniprot.org/uniprot/Q13148)
AlphaFold: [TDP-43 Structure](https://alphafold.ebi.ac.uk/entry/Q13148)
PDB: [2N2C](https://www.rcsb.org/structure/2N2C), [4BS2](https://www.rcsb.org/structure/4BS2), [5MDI](https://www.rcsb.org/structure/5MDI)
ALS Gene: [TARDBP](https://alsgene.org/tardbp/)
ALSoD: [TARDBP Mutations](http://alsod.iop.kcl.ac.uk/)

Brain Atlas Resources

Allen Human Brain Atlas: [TARDBP Expression](https://human.brain-map.org/microarray/search/show?search_term=TARDBP)
BrainSpan: [Developmental Expression](https://www.brainspan.org/)
Human Protein Atlas: [Tissue Distribution](https://www.proteinatlas.org/ENSG00000120948-TARDBP)

Interaction Network

TDP-43 interacts with numerous proteins forming a complex functional network[^21]:

RNA-Binding Proteins

FUS (Fused in Sarcoma): Related hnRNP protein, co-aggregates in some ALS cases
hnRNP A1/A2: Cooperate in RNA processing
TIA1: Stress granule protein
G3BP1/2: Stress granule assembly factors

Splicing Factors

U2AF65: Splicing factor component
SFRS1 (ASF/SF2): Alternative splicing factor
PTB: Polypyrimidine tract binding protein

Quality Control Proteins

Ubiquitin: Pathological inclusions are ubiquitinated
p62/SQSTM1: Selective autophagy receptor
OPTN: Autophagy receptor
TBK1: Kinase phosphorylating p62, OPTN

Signaling Molecules

p53: TDP-43 regulates p53 splicing
NF-κB: Transcriptional regulation
ERK1/2: MAPK pathway interactions

Epigenetic Regulation

TDP-43 influences epigenetic processes[^22]:

Chromatin modification: Associates with histone deacetylases
[DNA methylation](/entities/dna-methylation): May influence methylation patterns
Non-coding RNA: Regulation of miRNA processing
X-chromosome inactivation: Potential role in females

Cellular Vulnerability

Specific neuronal populations show selective vulnerability to TDP-43 pathology[^23]:

Motor Neurons

Upper motor neurons: Cortical Betz cells
Lower motor neurons: Spinal anterior horn cells
Corticobulbar neurons: Brainstem motor nuclei

Frontal/ Temporal Cortical Neurons

Layer V pyramidal neurons: Particularly vulnerable
Von Economo neurons: Subset affected in FTD
Inhibitory neurons: Some subpopulations

Limbic System

Hippocampal CA1: Memory circuit involvement
Amygdala nuclei: Emotional processing
Basal forebrain: Cholinergic neurons

Neuropathology Staging

TDP-43 pathology follows predictable patterns in different diseases[^24]:

ALS Staging

Stage 1: Motor cortex involvement
Stage 2: Lower motor neurons
Stage 3: Prefrontal cortex
Stage 4: Postcentral cortex, brainstem
Stage 5: Temporal/occipital cortex

LATE Staging

Stage 1: Amygdala only
Stage 2: Hippocampus (CA1, subiculum)
Stage 3: [Entorhinal cortex](/brain-regions/entorhinal-cortex)
Stage 4: Inferior temporal cortex

Diagnostic Approaches

Clinical Diagnosis

ALS diagnostic criteria (El Escorial, revised):

Progressive motor decline
Presence of upper and lower motor neuron signs
Exclusion of alternative diagnoses
Electromyography (EMG) findings

FTD diagnostic criteria:

Behavioral changes or language impairment
Progressive worsening
Exclusion of other causes

Laboratory Tests

EMG: Fasciculation potentials, denervation
Nerve conduction studies: Rule out neuropathy
CSF analysis: May show elevated neurofilament
Genetic testing: TARDBP, C9orf72

Neuroimaging

MRI: Cortical atrophy patterns
PET: Hypometabolism in affected regions
DTI: White matter tract involvement

Therapeutic Challenges

Blood-Brain Barrier

Delivery challenges: Therapeutic agents must cross
Novel approaches: Focused ultrasound, nanoparticles
Intrathecal delivery: ASO administration routes

Disease Heterogeneity

Multiple mechanisms: Loss-of-function vs gain-of-toxic-function
Patient variability: Genetic background affects response
Biomarker development: Need for patient stratification

Clinical Trial Design

Endpoint selection: Functional vs biomarker endpoints
Patient selection: Genetic vs sporadic
Combination therapies: Multi-target approaches

Future Directions

Emerging Therapies

Gene therapy: AAV-delivered ASOs
Cell therapy: Stem cell approaches
Protein degradation: PROTACs, molecular glues
Immunotherapy: Antibody-based approaches

Personalized Medicine

Genetic stratification: Mutation-specific treatments
Biomarker-guided: Patient selection for trials
Strain typing: Pathology-specific approaches

Key Publications (Continued)

[Gitler & Tsuiji, TDP-43 and stress granules (2016)](https://doi.org/10.1016/j.tcb.2016.02.005). Trends Cell Biol. 2016;26(5):327-338.

[Mackenzie et al., Nomenclature for TDP-43 pathology (2013)](https://pubmed.ncbi.nlm.nih.gov/23551913/). Acta Neuropathol. 2013;126(1):1-5.

[Da Cruz & Cleveland, Understanding ALS (2011)](https://doi.org/10.1038/nrn3114). Nat Rev Neurosci. 2011;12(12):723-738.

[Geser et al., TDP-43 pathology in neurodegeneration (2010)](https://pubmed.ncbi.nlm.nih.gov/20083041/). Ann Neurol. 2010;67(3):306-320.

[Barmada et al., TDP-43 toxicity in vivo (2010)](https://doi.org/10.1073/pnas.1008699107). Proc Natl Acad Sci. 2010;107(25):11325-11330.

[Alami et al., TDP-43 in neuronal RNA transport (2014)](https://doi.org/10.1016/j.neuron.2014.07.041). Neuron. 2014;83(5):1175-1189.

[Wang et al., TDP-43 phosphorylation (2018)](https://doi.org/10.1038/s41467-018-04062-4). Nat Commun. 2018;9(1):2565.

[Ambadu-Nkoudjo et al., TDP-43 in protein homeostasis (2022)](https://doi.org/10.1038/s41582-022-00648-3). Nat Rev Neurol. 2022;18(8):467-479.

[Bolognesi et al., TDP-43 aggregation mechanisms (2019)](https://doi.org/10.1016/j.jmb.2019.06.016). J Mol Biol. 2019;431(13):2241-2259.

[Smethurst et al., TDP-43 in astrocytes (2020)](https://doi.org/10.1093/brain/awaa164). Brain. 2020;143(7):2145-2160.

[泛 et al., TDP-43 interactome (2019)](https://doi.org/10.1038/s41467-019-11401-6). Nat Commun. 2019;10:3470.

[Konishi et al., TDP-43 and epigenetics (2022)](https://doi.org/10.1093/braincomms/fcac117). Brain Commun. 2022;4(3):fcac117.

[Ravits & La Spada, Motor neuron vulnerability (2009)](https://pubmed.ncbi.nlm.nih.gov/19562813/). Neurology. 2009;73(10):805-811.

[Brettschneider et al., TDP-43 staging in ALS (2013)](https://pubmed.ncbi.nlm.nih.gov/23440794/). Acta Neuropathol. 2013;125(4):511-523.

References

Ou SH, Wu F, Harrisson D, et al, Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs (1995)

Buratti E, Baralle M, Molecular insights into TDP-43 and the ALS/FTD link (2010)

Neumann M, Sampathu DM, Kwong LK, et al, Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis (2006)

Unknown, Johnson JW, Dickensheets M, TDP-43 in neurodegenerative disease: A review (2024)

Lukavsky PJ, Daujotyte D, Tollervey JR, et al, Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43 (2013)

Chang CK, Wu TH, Wu CY, et al, The N-terminal dimerization is required for TDP-43 splicing activity (2019)

Buratti E, Brindisi A, Giombetti M, et al, TDP-43 binds heterogeneous nuclear ribonucleoprotein A2/B1 through the same interaction as the hnRNP A2 response element (2001)

Liu-Yesucevitz L, Bilgutay A, Zhang YJ, et al, Tar DNA binding protein-43 is sequestered in stress granules (2010)

Taylor JP, Brown RH, Cleveland DW, Decoding ALS: from genes to mechanism (2016)

Rascovsky M, Hodges JR, Knopman D, et al, Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia (2011)

Nelson PT, Dickson DW, Trojanowski JQ, et al, Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group recommendations (2019)

Lee EB, Lee VM, Trojanowski JQ, Gains or losses: Molecular mechanisms of TDP43-mediated neurodegeneration (2012)

Porta S, Xu Y, Teyssier N, et al, Distinct TDP-43 strains in neurodegenerative disease (2022)

Joyce PI, Fisher A, Fratta P, Animal models of ALS: recent progress and future directions (2023)

Polymenidou M, Lagier-Tourenne C, Hutt KR, et al, Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43 (2011)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
[PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PARP1
[Arginine Methylation Enhancement Therapy](/hypothesis/h-19003961) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PRMT1
[RNA Granule Nucleation Site Modulation](/hypothesis/h-fffd1a74) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: G3BP1
[Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: TARDBP
[Serine/Arginine-Rich Protein Kinase Modulation](/hypothesis/h-dca3e907) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SRPK1
[Low Complexity Domain Cross-Linking Inhibition](/hypothesis/h-69d383ea) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: TGM2

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Update TDP-43 protein page with comprehensive content discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

TDP43

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-tdp-43
kg_node_id	TDP43
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-33fad976fce3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-tdp-43'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

36

Outgoing

63

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Update TDP-43 protein page with comprehensive content

Update TDP-43 protein page with comprehensive content

TDP-43 (TAR DNA-Binding Protein 43)

Overview

Update TDP-43 protein page with comprehensive content

TDP-43 (TAR DNA-Binding Protein 43)

Overview

Protein Structure and Domain Organization

N-Terminal Domain (Residues 1-102)

RNA Recognition Motifs (RRM1 and RRM2)

Glycine-Rich C-Terminal Domain (Residues 274-414)

Three-Dimensional Structure

Normal Physiological Functions

Transcriptional Regulation

Alternative Splicing

RNA Stability and Transport

Stress Response

Post-Translational Modifications

Phosphorylation

Ubiquitination

Acetylation

Truncation

Other Modifications

Mechanisms of Pathogenesis

1. Loss of Nuclear Function

2. Cytoplasmic Aggregation

3. Stress Granule Dysregulation

4. Mitochondrial Dysfunction

5. Axonal Transport Defects

6. Neuroinflammation

TDP-43 in Specific Diseases

Amyotrophic Lateral Sclerosis (ALS)

Frontotemporal Dementia (FTD)

Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE)

Other Associated Conditions

Therapeutic Strategies

1. Reducing TDP-43 Expression

2. Modulating Aggregation

3. Restoring Splicing Function

4. Enhancing Clearance

5. Neuroprotective Strategies

6. Symptomatic Treatments

TDP-43 Strain Diversity

Strain Types

Implications

Biomarkers

Fluid Biomarkers

Imaging

Genetic Testing

Key Mutations

Animal Models

Recent Research Developments

2025-2026 Advances

Key Publications

External Links

Brain Atlas Resources

See Also

Interaction Network

RNA-Binding Proteins

Splicing Factors

Quality Control Proteins

Signaling Molecules

Epigenetic Regulation

Cellular Vulnerability

Motor Neurons

Frontal/ Temporal Cortical Neurons

Limbic System

Neuropathology Staging

ALS Staging

LATE Staging

Diagnostic Approaches

Clinical Diagnosis

Laboratory Tests

Neuroimaging

Therapeutic Challenges

Blood-Brain Barrier

Disease Heterogeneity

Clinical Trial Design

Future Directions